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Abstract
Background
Whether inpatient services can be successfully substituted by office-based services has
been debated for many decades, but the evidence is still inconclusive. This study aims to
investigate the effect of office-based care on use and the expenditure for other healthcare
services in patients with type II diabetes (T2D).
Methods
A generalized propensity score matching approach was used on pooled Medical Expendi-
ture Panel Survey (MEPS) data for 2000–2012 to explore a dose-response effect. Patients
were matched by using a comprehensive set of variables selected following a standard
model on access to care.
Findings
Office-based care (up to 5 visits/year) acts as a substitute for other healthcare services and
is associated with lower use and expenditure for inpatient, outpatient and emergency care.
After five visits, office-based care becomes a complement to other services and is associ-
ated with increases in expenditure for T2D. Above 20 to 26 visits per year, depending on the
healthcare service under consideration, the marginal effect of an additional office-based
visit becomes non-statistically significant.
Conclusions
Office-based visits appear to be an effective instrument to reduce use of inpatient care and
other services, including outpatient and emergency-care, in patients with T2D without any
increase in total healthcare expenditure.
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Introduction
During the last 20 years, the management of major chronic diseases like diabetes and cardiovascu-
lar diseases has gradually shifted from the hospital setting to ambulatory care [1]. The key axiom
behind this approach is that high-quality office-based care delays the development of chronic dis-
eases and reduces the probability of costly episodes of inpatient care. Under this assumption,
higher use of office-based services is associated with lower use of inpatient care. In contrast, a
competing hypothesis is that higher use of ambulatory services might prompt additional referrals
and investigations, increasing the probability of hospitalization. Furthermore, sicker patients
might simply consume higher levels of both office-based and inpatient care. Under these two
alternative scenarios, office-based care would be associated with higher use of inpatient care.
Whether inpatient services can be successfully substituted by office-based services has been
debated for many decades [2] but the evidence is still inconclusive, particularly regarding any
quantification of the substitution effect. A systematic review assessing the primary-secondary
care interface [3] concludes that shifting the balance between the two would be possible but
the study fails to quantify the substitution effect. Van Dijk and colleagues [4] do not find any
statistical association between higher use of general practice services and referral to other
healthcare services. A similar study [5] concludes that primary care services are a substitute for
specialty outpatient care but not for inpatient care. Zhao and colleagues [6] suggest that this
may happen because primary and hospital care would be linked through a J-shaped associa-
tion. In other words, ambulatory care may gradually shift from being a substitute for hospital
care to becoming a complement.
Type II diabetes (T2D) provides an excellent case-study to assess whether ambulatory care
may act as a substitute for inpatient care. First, T2B management has to be adjusted over time
as the patient’s clinical conditions evolve [7]. Additionally, poor management of T2D rapidly
leads to hospitalization due to the development of complications [8]. Second, quality assess-
ment guidelines published by the Agency for Healthcare Research and Quality [9] include
T2D as one of the chronic diseases for which office-based care may successfully prevent hospi-
tal admission for uncontrolled diabetes. Third, T2D is highly prevalent in the US with 9.3% of
the population being affected by this disease [10].
The primary objective of this paper is to investigate the association between use of office-
based care and the use and expenditure for inpatient care and other healthcare services in indi-
viduals affected by T2D. More specifically, this study examines whether higher use of office-
based care prevents subsequent use of other healthcare services or whether healthcare services
complement each other. An additional set of analyses quantify the potential spillover effects of
office-based visits on inpatient care and total expenditure for any disease.
Methods
Data and sample
Data for this analysis was extracted from the 1997 to 2012 waves of the Medical Expenditure
Panel Survey (MEPS) [11]. MEPS is an ongoing annual survey collecting data on healthcare
utilization and expenditure for the US civilian non-institutionalized population. For each indi-
vidual, MEPS reports data on demography, socio-economic status, type of health insurance
coverage and health status. In addition, MEPS draw on administrative data to report use and
expenditure of different healthcare services for up to six healthcare conditions identified by
ICD-9-CM codes. Sampled individuals are followed for 2 consecutive years. Nominal expendi-
tures and charges are expressed in United States Dollars (USD), year 2010 values, using event-
specific product price indexes [12,13].
Office-based visits and hospitalizations for patients with diabetes
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To be included in the study sample, individuals had to meet three main criteria (further
information in the S1 appendix) selected to minimize the risk of spurious correlations linked
to causalities and unmeasured complexities that may still exist, even after matching. First, indi-
viduals had to be diagnosed with T2D. Patients with T2D were identified either through self-
reporting or because patients’ clinical records reported at least one contact with the healthcare
service under the ICD-9-CM code for T2D (code 250 and subcategories). Second, patients had
not used inpatient services for T2D during the first year of follow up. Third, patients had to be
included in two consecutive waves of the survey (i.e. a two year follow-up).
Methodological overview
This study assesses whether having used office-based care for any condition during the first
year of the follow-up (i.e. the intervention) had any effect on the use and expenditure for inpa-
tient care and other healthcare services (i.e. the study outcomes) for T2D (i.e. code 250 and
subcategories as first medical condition) during the second year of the follow up. In an addi-
tional set of analyses the outcomes are extended to cover any disease (i.e. any ICD-9-CM
code).
The study was carried out in three steps. The first step involved the calculation of a general-
ized propensity score (GPS) corresponding to the probability that an individual in the sample
receives a specific quantity of the intervention (i.e. number of office-based care visits), condi-
tional on a set of explanatory variables. The use of a GPS adjusts for the pre-treatment observ-
able differences between different groups of individuals and reduces the impact of the
selection bias when estimating the treatment effect [14]. Compared to other parametric
approaches, the approach based on matching does not require any assumption about the rela-
tionship existing between the dependent and the explanatory variables because the effective-
ness is calculated on the averaged difference across matched individuals. Furthermore, only
comparable individuals are considered in the evaluation process.
In the second step, individuals are split in the treatment and control group. These two
groups are compared to verify that only similar individuals are used in the final phase of the
analysis. The balance of single explanatory variables across the two groups is validated by t-
tests.
The third and final step of the analyses involves the matching of the individuals and the cal-
culation of the treatment effect. Individuals of the treatment and control groups with similar
scores are paired during the matching stage. The outcome under study is then compared
across the matched individuals to gauge the treatment effect and the dose-response function.
All the analyses were carried out in Stata (v 15.1).
Study variables
This analysis assesses the effect of office-based visits on fourteen different outcomes. More spe-
cifically, the study outcomes include: total expenditure for T2D; service-specific use and
expenditure for T2D for the following healthcare services: inpatient care (with and without
surgery), outpatient care, drug prescriptions, and emergency care; total healthcare expenditure
for any disease; use and expenditure for inpatient care for any disease. The latter three out-
comes are included to assess any potential spill over effect that T2D management may have on
other diseases. Use of services is modelled as a dichotomous variable (use of a given service vs
no use of that service) while expenditure outcomes are modelled as continuous variables. The
main characteristics of the outcomes included in the study are summarized in Table 1.
Use of office-based care is the treatment. Office-based care is modelled as a continuous vari-
able to explore the dose-response effect of providing an additional office-based visit on the
Office-based visits and hospitalizations for patients with diabetes
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studied outcome. To allow for a non-linear relationship, the analysis evaluates the effect of
each additional office-based visit from 1, up to a maximum of 34.
A comprehensive set of independent variables is used to calculate the GPS. Variables were
selected to maximize the precision of the matching estimator. Based on Andersen’s framework
on access to medical care [15] we included explanatory variables capturing demography,
socio-economic status, health-seeking behaviours, probability of access to care, health status
and presence of risk factors. The set includes gender, age, race/ethnicity, region of residence,
marital status, insurance status, health status, body-mass index (BMI) category, total number
of comorbidities beyond T2D and period. Additional information on the variables can be
found in the S1 appendix.
Calculation of the generalized propensity scores and the matching
estimators
This study was carried out using the GPS [16] as this approach can model the treatment as a
continuous variable and can be used to study the dose-response effect of providing an addi-
tional office-based visit [17].
The analyses are mainly based on the approach developed by Guardabascio and Ventura
[16] which estimates the GPS by using a generalized linear model. The GPS is combined with
the treatment level to estimate both the conditional expectation of the outcome and the dose-
response function at increasing quantities of treatment. Based on the Akaike information crite-
rion [18,19], a gamma distribution with log-link was selected as the best combination to fit our
data. The polynomial function used to estimate the conditional expectation of the outcome
includes both the GPS and the treatment level and allows for interaction between the two so as
to capture nonlinearities. The dose-response effect is calculated for single treatment gaps.
Assessment of uncertainty and sensitivity analysis
Assessment of uncertainty was carried out through bootstrapping [20], which incorporates the
estimation error of the GPS and of the other predicting parameters. The sensitivity analysis
Table 1. Study outcomes and their key characteristics.
Name of the outcome Included in the Number of categories
Inpatient care–access Main analysis 2 (use vs no use)
Inpatient care–expenditure Main analysis Continuous (USD)
Inpatient care (surgery)–access Main analysis 2 (use vs no use)
Inpatient care (surgery)—expenditure Main analysis Continuous (USD)
Outpatient care–access Main analysis 2 (use vs no use)
Outpatient care–expenditure Main analysis Continuous (USD)
Drug prescription–access Main analysis 2 (use vs no use)
Drug prescription—expenditure Main analysis Continuous (USD)
Emergency care–access Main analysis 2 (use vs no use)
Emergency care–expenditure Main analysis Continuous (USD)
Total expenditure Main analysis Continuous (USD)
Inpatient care–access Additional analysis 2 (use vs no use)
Inpatient care–expenditure Additional analysis Continuous (USD)
Total expenditure Additional analysis Continuous (USD)
Note: the main analysis is limited to T2D (i.e. ICD-9-CM code 250 and subcategories as first medical condition); the
additional analysis cover all the conditions (i.e. any ICD-9-CM code).
https://doi.org/10.1371/journal.pone.0209197.t001
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was carried out by randomly replacing the data in memory within the intervals evaluated dur-
ing the calculations. All the statistics were resampled 1500 times.
Outpatient care and drug use may have a complementary role to office-based care to
decrease the hospitalization rate. This further source of uncertainty is tested in an additional
set of analyses by including drug expenditure and outpatient expenditure in the set of explana-
tory variables used to calculate the GPS. More information for this set of analyses can be found
in the S1 appendix.
Results
Population characteristics and use of healthcare services
As the number of office-based visits increases (Table 2, with results of the Kruskal-Wallis H
test in the S1 appendix), individuals are more likely to be males, older and of white non-his-
panic ethnicity. Following a similar pattern, the prevalence of those covered by either private
insurance or only by public insurance increases compared to those paying out-of-pocket for
office-based visits. The health status does not seem to vary across the different intervention
groups, although individuals with 20 or more office-based visits report a worse health status.
Finally, individuals with higher use of office-based visits are more likely to have a higher num-
ber of comorbidities and BMI.
Between 2% and 3% of the study sample used inpatient care for T2D during the second year of
their follow up (Table 3). Surgery was performed in a small minority of these patients. No clear
trend can be discerned for inpatient expenditure as the number of office-based visits increases but
undergoing surgery doubles the expenditure for inpatient care. Use of outpatient care and emer-
gency care show U-shaped trends while drug expenditure and total expenditure for T2D show an
increasing trend as the number of office-based visits increases. These findings are broadly con-
firmed by the Kruskal-Wallis H test and the ANOVA test (results reported in the S1 appendix).
Propensity scores and preparatory analyses
All the explanatory variables used to calculate the GPS show statistically significant coeffi-
cients. Gender, age and number of comorbidities show a P-value below 0.001. Paying out-of-
pocket for office-based visits is another strong predictor of lower access to care (P<0.001). T-
tests to validate the covariate balancing confirm that only similar individuals are used to calcu-
late the effect of the intervention. Coefficients of the regressions and results of the t-tests are
reported in the S1 appendix.
Dose-response effect of an additional office-based visit
Use of office-based visits and use and expenditure for inpatient care (with and without sur-
gery), outpatient care and emergency care are linked by a complex, non-linear, relationship
(Table 4 and graphical representation in the S1 appendix) characterized by three phases. In a
first phase, and up to a maximum of 4–5 visits per year, office-based care acts as a substitute
for other healthcare services and is associated with lower use and expenditure for inpatient,
outpatient and emergency care. The incremental substitution effect is greatest when the first
office-based visit is provided and decreases as the number of office-based visits increases. So,
for example, compared to patients without any office-based visit in year 1, patients with one
office-based visit in year one report a 77.65 USD (standard error: 36.98 USD) reduction in
expenditure for inpatient care in year 2. Similarly, patients with two office-based visits in year
1 reports a further 47.59 USD (standard error: 23.60 USD) reduction in expenditure for inpa-
tient care in year 2, compared to patients that reported only 1 office-based visit in year 1.
Office-based visits and hospitalizations for patients with diabetes
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In a second phase, between 5 and 20–26 office-based visits (according to the healthcare ser-
vice under study), office-based visits become a complement to other types of care. In this group
of patients, each additional office-based visit is associated with an increase in use and expendi-
ture for other healthcare services. Referring to the same example above, patients with 8 office-
based visits in year 1 reports a 9.94 USD (standard error: 4.80 USD) increase in expenditure for
inpatient care in year 2, compared to patients that reported 7 office-based visits in year 1.
Table 2. Sample characteristics (prevalence rates) of patients by number of office-based visits.
Number of visits 0+ 0 1 2 3 4–5 6–9 10–19 20+
Sample 13,641 1,189 1,155 1,286 1,227 2,024 2,586 2,625 1,549
Gender
Males 0.445 0.554 0.501 0.485 0.471 0.440 0.429 0.397 0.376
Females 0.555 0.446 0.499 0.515 0.529 0.560 0.571 0.603 0.624
Age
0–34 0.061 0.142 0.086 0.077 0.068 0.056 0.040 0.042 0.033
35–64 0.552 0.669 0.668 0.599 0.588 0.567 0.517 0.468 0.495
65–80 0.304 0.161 0.207 0.268 0.266 0.294 0.347 0.378 0.364
80+ 0.083 0.029 0.040 0.056 0.079 0.083 0.096 0.112 0.108
Race
White non-hisp 0.474 0.288 0.344 0.395 0.408 0.457 0.517 0.569 0.625
White-hispanic 0.224 0.368 0.281 0.235 0.262 0.221 0.199 0.187 0.136
Black 0.226 0.242 0.275 0.272 0.258 0.250 0.216 0.180 0.178
Asian 0.043 0.070 0.068 0.063 0.051 0.041 0.038 0.029 0.018
Others 0.033 0.032 0.032 0.035 0.021 0.031 0.030 0.034 0.043
Region
Northeast 0.152 0.121 0.146 0.131 0.157 0.144 0.151 0.158 0.194
Midwest 0.189 0.156 0.158 0.159 0.185 0.208 0.191 0.204 0.204
South 0.428 0.441 0.461 0.465 0.438 0.437 0.426 0.419 0.364
West 0.232 0.283 0.235 0.245 0.220 0.211 0.232 0.219 0.238
Marital status
Single 0.114 0.170 0.152 0.137 0.129 0.107 0.091 0.089 0.104
Married 0.550 0.551 0.571 0.561 0.543 0.560 0.566 0.530 0.524
Widowed/divorce/separ 0.336 0.279 0.278 0.302 0.328 0.333 0.343 0.381 0.372
Insurance
Public only 0.524 0.458 0.525 0.532 0.508 0.540 0.535 0.522 0.550
Private 0.373 0.267 0.281 0.340 0.383 0.363 0.397 0.429 0.421
Out-of-pocket 0.103 0.276 0.194 0.128 0.109 0.098 0.068 0.049 0.029
Period
1997–2000 0.050 0.050 0.060 0.047 0.049 0.044 0.056 0.053 0.041
2001–2004 0.262 0.236 0.212 0.230 0.237 0.253 0.291 0.300 0.261
2005–2008 0.307 0.277 0.294 0.279 0.281 0.315 0.303 0.320 0.356
2009–2012 0.381 0.437 0.434 0.443 0.433 0.387 0.350 0.327 0.341
Health status
Median value good good good good good good good good fair
Body-mass index
Median value (Kg/m2) 30.2 29.2 30.0 29.8 29.4 30.1 30.5 30.4 31.2
Number of comorbidities
Median value 4.0 1.0 2.0 3.0 3.0 4.0 5.0 7.0 9.0
Note: hisp is Hispanics; separ is separated.
https://doi.org/10.1371/journal.pone.0209197.t002
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Finally, as the number of office-based visits further increases (i.e. above 20 to 26 office-
based visits), the marginal effect of an additional office-based visit becomes smaller and non-
statistically significant.
Conversely, the probability of drug prescription and its associated expenditure increases as
the number of office-based visits increases. So, for example, the first office-based visit in year 1 is
associated with an additional 41.21 USD (standard error: 5.12 USD) in the expenditure for drug
prescription in year 2, compared to patients that did not report any office-based visit in year 1.
However, after the ninth office-based visit, the probability of additional prescription decreases
and the incremental expenditure becomes negligible. Each additional office-based visit after the
second visit is also associated with an increase in the total healthcare expenditure on T2D.
Results of the sensitivity analysis (reported in the S1 appendix) confirm the findings
reported above, even when drug expenditure and outpatient expenditure are included in the
set of explanatory variables used to calculate the GPS. This supports the hypothesis that the
effect produced by the use of office-based visits is relatively stable at various levels of expendi-
ture for other healthcare services that may have a complementary role to office-based visits in
avoiding use of hospital services.
An additional set of analyses (reported in the S1 appendix) explores the impact of office-
based visits on total healthcare expenditure and probability of access to inpatient care for any
diagnosis. In this analysis, general inpatient utilization and expenditure start increasing after
the first visit suggesting that office-based visits may prompt additional care for diseases not
directly related to T2D.
Discussion
This study has focused on patients with T2D to investigate the relationship between number of
office-based visits and use and expenditure for inpatient care and other healthcare services.
Findings shows that office-based care (up to 4–5 visits per year) may be a substitute for other
Table 3. Use of inpatient care services and associated expenditure by number of office-based visits.
Number of visits 0 1 2 3 4–5 6–9 10–19 20+
Sample 1,189 1,155 1,286 1,227 2,024 2,586 2,625 1,549
Inpatient care
Access (rate) 0.032 0.018 0.012 0.020 0.012 0.017 0.019 0.024
median expenditure 4,018 7,493 6,964 9,543 7,109 5,868 6,586 6,678
Inpatient care with surgery
Access (rate) 0.008 0.002 0.000 0.005 0.002 0.004 0.005 0.006
median expenditure 8,984 63,546 - 15,235 10,694 10,398 12,149 14,582
Outpatient care
Access (rate) 0.061 0.048 0.033 0.053 0.050 0.054 0.067 0.085
median expenditure 259 187 180 206 157 222 281 227
Drug prescription
Access (rate) 0.691 0.766 0.800 0.826 0.835 0.831 0.852 0.841
median expenditure 252 419 426 571 581 635 781 867
Emergency care
Access (rate) 0.045 0.026 0.022 0.026 0.017 0.019 0.022 0.028
median expenditure 174 514 304 368 450 380 483 443
Total expenditure 179 340 364 555 609 703 925 1,075
Note: expenditures are reported in 2010 USD.
https://doi.org/10.1371/journal.pone.0209197.t003
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Table 4. Dose-response effect of use of office-based care on use and expenditure for other healthcare services for T2D by number of office-based visits.
Office-based
visits
Inpatient care Inpatient care—surgery Outpatient care Drug prescription Emergency care total
expenditureaccess expenditure access expenditure access expenditure access expenditure access Expenditure
effect SE effect SE effect SE effect SE effect SE effect SE effect SE effect SE effect SE effect SE effect SE
0–1 -5.46 (2.25)� -77.65 (36.98)� -1.18 (1.27) -45.55 (32.13) -2.49 (2.41) -20.53 (10.39)� 41.21 (5.12)� 126.06 (14.97)� -6.81 (2.45)� -1.16 (3.14) 44.81 (45.67)
1–2 -2.93 (1.09)� -47.59 (23.60)� -0.63 (0.62) -26.84 (20.23) -1.05 (1.55) -12.63 (6.70) 25.58 (2.72)� 94.72 (9.59)� -3.7 (1.14)� -0.78 (2.11) 53.07 (29.12)
2–3 -1.64 (0.59)� -26.91 (14.49) -0.34 (0.36) -14.03 (12.11) -0.06 (1.02) -7.16 (4.16) 16.34 (1.49)� 71.9 (5.95)� -2.17 (0.61)� -0.49 (1.40) 57.54 (17.82)�
3–4 -0.89 (0.34)� -12.75 (8.48) -0.15 (0.22) -5.33 (6.74) 0.64 (0.66) -3.39 (2.44) 10.6 (0.83)� 55.18 (3.57)� -1.28 (0.34)� -0.28 (0.91) 59.54 (10.36)�
4–5 -0.4 (0.20)� -3.15 (4.96) -0.01 (0.14) 0.52 (3.67) 1.14 (0.43)� -0.82 (1.32) 6.86 (0.50)� 42.89 (2.18)� -0.73 (0.20)� -0.11 (0.59) 59.95 (6.09)�
5–6 -0.06 (0.13) 3.24 (3.79) 0.09 (0.09) 4.37 (2.99) 1.48 (0.30)� 0.92 (0.72) 4.32 -(0.39) 33.81 (1.69)� -0.35 (0.14)� 0.02 (0.40) 59.36 (4.87)�
6–7 0.17 (0.12) 7.38 (4.15) 0.16 (0.07)� 6.82 (3.66) 1.71 (0.27)� 2.07 (0.66)� 2.55 (0.41)� 27.1 (1.77)� -0.09 (0.13) 0.12 (0.32) 58.17 (5.51)�
7–8 0.34 (0.14)� 9.94 (4.80)� 0.22 (0.07)� 8.29 (4.39) 1.86 (0.29)� 2.79 (0.82)� 1.31 (0.46)� 22.12 (2.00)� 0.09 (0.15) 0.2 (0.31) 56.63 (6.43)�
8–9 0.46 (0.17)� 11.39 (5.31)� 0.26 (0.09)� 9.07 (4.89) 1.94 (0.33)� 3.23 (0.97)� 0.42 (0.50) 18.44 (2.19)� 0.22 (0.17) 0.26 (0.33) 54.92 (7.13)�
9–10 0.55 (0.19)� 12.07 (5.60)� 0.29 (0.11)� 9.39 (5.17) 1.98 (0.36)� 3.46 (1.06)� -0.21 (0.53) 15.71 (2.32)� 0.32 (0.18) 0.31 (0.36) 53.14 (7.56)�
10–11 0.61 (0.20)� 12.22 (5.73)� 0.31 (0.12)� 9.38 (5.28) 1.98 (0.38)� 3.54 (1.10)� -0.66 (0.55) 13.71 (2.39)� 0.38 (0.20)� 0.34 (0.37) 51.38 (7.78)�
11–12 0.65 (0.21)� 12.00 (5.74)� 0.33 (0.13)� 9.15 (5.28) 1.96 (0.39)� 3.52 (1.11)� -0.97 (0.56) 12.24 (2.42)� 0.43 (0.20)� 0.38 (0.38) 49.68 (7.85)�
12–13 0.67 (0.22)� 11.55 (5.67)� 0.33 (0.14)� 8.79 (5.19) 1.93 (0.40)� 3.44 (1.10)� -1.18 (0.56)� 11.18 (2.42)� 0.47 (0.21)� 0.40 (0.38) 48.07 (7.81)�
13–14 0.68 (0.23)� 10.95 (5.54)� 0.34 (0.14)� 8.34 (5.05) 1.88 (0.41)� 3.32 (1.07)� -1.32 (0.56)� 10.42 (2.40)� 0.49 (0.21)� 0.42 (0.38) 46.55 (7.70)�
14–15 0.69 (0.23)� 10.25 (5.39) 0.33 (0.15)� 7.84 (4.89) 1.82 (0.41)� 3.17 (1.04)� -1.4 (0.55)� 9.89 (2.37)� 0.50 (0.22)� 0.44 (0.38) 45.14 (7.56)�
15–16 0.68 (0.24)� 9.51 (5.22) 0.33 (0.15)� 7.31 (4.72) 1.76 (0.41)� 3.00 (1.00)� -1.44 (0.55)� 9.54 (2.35)� 0.51 (0.22)� 0.45 (0.37) 43.84 (7.40)�
16–17 0.68 (0.24)� 8.75 (5.05) 0.32 (0.15)� 6.79 (4.55) 1.7 (0.41)� 2.82 (0.97)� -1.46 (0.54)� 9.31 (2.32)� 0.52 (0.22)� 0.46 (0.37) 42.64 (7.23)�
17–18 0.67 (0.24)� 8.00 (4.89) 0.31 (0.16)� 6.27 (4.39) 1.64 (0.41)� 2.65 (0.94)� -1.45 (0.54)� 9.18 (2.29)� 0.52 (0.22)� 0.47 (0.36) 41.54 (7.07)�
18–19 0.65 (0.25)� 7.26 (4.75) 0.3 (0.16) 5.77 (4.24) 1.58 (0.41)� 2.47 (0.92)� -1.43 (0.53)� 9.12 (2.27)� 0.51 (0.22)� 0.48 (0.36) 40.53 (6.93)�
19–20 0.64 (0.25)� 6.56 (4.62) 0.29 (0.17) 5.29 (4.10) 1.52 (0.41)� 2.31 (0.90)� -1.4 (0.53)� 9.11 (2.25)� 0.51 (0.23)� 0.48 (0.35) 39.62 (6.79)�
20–21 0.62 (0.26)� 5.88 (4.51) 0.28 (0.17) 4.83 (3.98) 1.46 (0.41)� 2.15 (0.89)� -1.36 (0.53)� 9.14 (2.24)� 0.50 (0.23)� 0.49 (0.35) 38.78 (6.68)�
21–22 0.61 (0.26)� 5.25 (4.41) 0.26 (0.18) 4.40 (3.88) 1.41 (0.42)� 1.99 (0.89)� -1.31 (0.52)� 9.2 (2.23)� 0.50 (0.23)� 0.49 (0.34) 38.02 (6.58)�
22–23 0.59 (0.27)� 4.65 (4.33) 0.25 (0.18) 4.00 (3.79) 1.36 (0.42)� 1.85 (0.89)� -1.27 (0.52)� 9.28 (2.22)� 0.49 (0.24)� 0.50 (0.34) 37.32 (6.49)�
23–24 0.58 (0.27)� 4.09 (4.27) 0.24 (0.19) 3.63 (3.72) 1.31 (0.43)� 1.72 (0.90) -1.22 (0.52)� 9.37 (2.22)� 0.49 (0.24)� 0.50 (0.34) 36.69 (6.42)�
24–25 0.56 (0.28)� 3.57 (4.22) 0.23 (0.19) 3.28 (3.66) 1.27 (0.44)� 1.59 (0.91) -1.17 (0.52)� 9.47 (2.22)� 0.48 (0.25) 0.50 (0.33) 36.12 (6.37)�
25–26 0.55 (0.29) 3.09 (4.18) 0.22 (0.20) 2.96 (3.62) 1.23 (0.45)� 1.47 (0.92) -1.12 (0.52)� 9.57 (2.23)� 0.47 (0.25) 0.50 (0.33) 35.59 (6.32)�
26–27 0.53 (0.29) 2.64 (4.15) 0.21 (0.21) 2.66 (3.58) 1.19 (0.45)� 1.36 (0.93) -1.07 (0.52)� 9.68 (2.23)� 0.47 (0.26) 0.50 (0.33) 35.12 (6.29)�
27–28 0.52 (0.30) 2.22 (4.13) 0.2 (0.21) 2.38 (3.56) 1.16 (0.46)� 1.26 (0.95) -1.03 (0.53) 9.78 (2.24)� 0.46 (0.27) 0.51 (0.33) 34.68 (6.27)�
28–29 0.5 (0.31) 1.83 (4.12) 0.19 (0.22) 2.12 (3.54) 1.12 (0.47)� 1.17 (0.96) -0.98 (0.53) 9.89 (2.25)� 0.45 (0.27) 0.51 (0.33) 34.28 (6.25)�
29–30 0.49 (0.32) 1.48 (4.11) 0.18 (0.23) 1.88 (3.53) 1.09 (0.48)� 1.08 (0.98) -0.94 (0.53) 9.99 (2.26)� 0.45 (0.28) 0.51 (0.33) 33.92 (6.24)�
30–31 0.48 (0.33) 1.15 (4.11) 0.17 (0.23) 1.67 (3.52) 1.07 (0.49)� 1.00 (0.99) -0.90 (0.53) 10.09 (2.27)� 0.44 (0.28) 0.51 (0.33) 33.59 (6.23)�
31–32 0.47 (0.33) 0.84 (4.12) 0.16 (0.24) 1.46 (3.52) 1.04 (0.50)� 0.92 (1.01) -0.86 (0.53) 10.18 (2.28)� 0.44 (0.29) 0.51 (0.33) 33.29 (6.23)�
32–33 0.46 (0.34) 0.56 (4.12) 0.15 (0.25) 1.28 (3.52) 1.02 (0.51)� 0.85 (1.03) -0.83 (0.54) 10.27 (2.29)� 0.44 (0.30) 0.51 (0.33) 33.01 (6.23)�
33–34 0.45 (0.35) 0.30 (4.13) 0.15 (0.26) 1.10 (3.52) 0.99 (0.52) 0.79 (1.04) -0.8 (0.54) 10.35 (2.30)� 0.43 (0.30) 0.51 (0.33) 32.76 (6.23)�
34–35 0.44 (0.36) 0.05 (4.14) 0.14 (0.27) 0.94 (3.53) 0.97 (0.53) 0.73 (1.05) -0.76 (0.54) 10.44 (2.30)� 0.43 (0.31) 0.51 (0.33) 32.52 (6.23)�
Note. The numbers in effect columns represent the effect of an additional office-based visit on the probability of use or the expenditure for any other healthcare service.
� 95% confidence interval does not include 0; probabilities are expressed per 1000 individuals; expenditures are reported in 2010 USD; SE: standard error.
https://doi.org/10.1371/journal.pone.0209197.t004
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healthcare services without increasing total expenditure on T2D. However, higher use of
office-based care may increase total healthcare expenditure for any disease.
Our results cannot be directly compared with the study by Zhao and colleagues [6] due to
differences in the methodology and the sample selection. In its analysis on diabetes, Zhao con-
cludes that ambulatory care and hospitalization would be inversely associated for patients with
less than 15 clinic visits per year while the association would become positive thereafter. A
threshold of 15 visits per year is also found in Zhao’s analysis on any chronic disease. In this
latter case (but not for diabetes), the authors carry out an additional analysis with a more
refined methodology concluding that the threshold is, in fact, about 5 visits per year, which is
broadly aligned with our results.
Strengths and limitations
This study builds on methodological advances from economics and social policy [21,22] to test
the use of GPS in a dose-response analysis in the field of diabetes care.
The main issue potentially affecting our results may arise due to some endogeneity caused
by unobserved characteristics and omitted variables. For example, unobserved sickness may
modify the likelihood of using office-based services. We address this concern in two ways.
First, this analysis includes a set of variables to stratify patients with varying risks of health uti-
lization. Self-reported health, in particular, has been showed to be a good predictor of health-
care services use [23]. Second, our models account for a wide-ranging set of explanatory
variables capturing all the main dimensions included in the Andersen’s model on access to
care [15]. So, it is likely that potentially unobserved characteristics, if any, would affect only a
minority of patients. In any case, any endogeneity would make our results more conservative
as sicker people tend to have higher use of office-based services.
The inclusion of the level of glycated haemoglobin A1c (HbA1c) in the matching estimator
would have provided a stronger instrument to capture unobserved sickness as it is a good indi-
cator to quantify the risk of complications caused by diabetes [24]. Unfortunately, this was not
possible because MEPS does not report this dimension. It cannot be excluded that in the analy-
ses presented in this chapter interventions and controls had different levels of HbA1c. If this
was to be the case, results may overestimate or underestimate the true effect of the intervention
depending on whether patients respectively in the intervention or the control group have a
lower level of HbA1c.
A second issue may arise from simultaneity and causality. We address simultaneity by
studying lagged use of office-based services as opposed to use in the same year. However, we
cannot exclude the possibility that this issue may still be associated with the few patients that
had used office-based care at the end of the first year and used other healthcare services at the
beginning of the second year. The causality assumption is addressed by focusing on patients
that used office-based care in year 1 and other healthcare services in year 2 and by excluding
those patients that had access to inpatient care during the first year of the follow up. The cau-
sality assumption is further strengthened by focusing on a set of medical conditions that are
exclusive short-term consequences of ill-treatment for T2D [7,24]. Conversely, the exclusion
of other longer-term complications [25] means that our results should be considered as con-
servative and that office-based care may, if anything, have a stronger substitution effect than
reported here.
Finally, the study has not examined the impact of increased ambulatory care on the health
of T2D patients. Whilst this issue was beyond the scope of this study, it would be a useful area
for future research, especially given a longer panel of observations. Self-reported health status
contributes to the calculation of the GPS and the matching. Therefore, this study shows the
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potential effect of office-based visits ignoring any additional health benefit. Our view is that,
once that these additional health benefits are taken into account, the effects of improved access
to office-based care on reduced hospitalizations are likely to increase further.
Policy implications and conclusion
Findings of this study have important implications for policymaking and healthcare manage-
ment at the national and local level. Office-based visits appear to be an efficient way to decrease
use of inpatient care as well as other healthcare services, including outpatient care and emer-
gency room. Thus, at least in the case of T2D, office-based care could be used as an effective
substitute for inpatient care. Ambulatory care reduces the workload of other healthcare ser-
vices and avoids hospitalizations for patients without increasing hospital expenditure for T2D.
The most cost-effective approach appears to be to provide two office-based visits per year as
this option minimizes access to other healthcare services without increasing total expenditure.
Further research in the field should look at barriers hindering an optimal use of office-based
care at the individual and the system level. This would provide evidence to design effective pol-
icy actions to tackle suboptimal use of office-based services.
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